Detection of gemcitabine-resistant genes expression in six lung cancer cell lines using real-time fluorogentic quantitative PCR

Tumor

Volumn 28, Issue 3, 2008, Pages 228-231

  Lin, Li ^a   Liu, Xiao Qing ^a   Wang, Wei Xia ^a   Wang, Sheng Qi ^b   Song, San Tai ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Carcinoma, non small cell lung; Drug resistance, neoplasm; Gene expression

Indexed keywords

BETA ACTIN; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; CANCER CELL; CELL ASSAY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE IDENTIFICATION; GIANT CELL CARCINOMA; HUMAN; HUMAN CELL; IC 50; LUNG ADENOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 77953390515     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2008.03.012     Document Type: Article

References (9)

1. ROSELL R, CRINO L, DANENBERG K, et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer[J]. Semin Oncol,2003,30(4 Suppl 10):19-25.
2. SARRIES C, HAURA EB, ROIG Bl, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer[J]. Pharmacogenomics, 2002,3(6):763-780.
3. PITTERLE DM, KIM YC, JOLICOEUR E Ml, et al. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1) [J]. Mamm Genome, 1999,10(9):916-922.
4. BEPLER G, ZHENG Z, GAUTAM A, et al. Ribonucleotide reductase M1 gene promoter activity polymorphisms, population frequencies and clinical relevance [J]. Lung Cancer, 2005, 47(2): 183-192.
5. ROSELL R, DANENBERG KD, ALBEROLA V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients[J]. Clin Cancer Res,2004,10(4):1318-1325.
6. BEPLER G, SHARMA S, CANTOR A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with NSCLC[J]. J Clin Oncol, 2004,22(10):1878-1885.
7. DAVIDSON JD, MA L, FLAGELLA M, et al. An increase in the expression of RRM1 is associated with gemcitabine resistance in NSCLC cell lines[J]. Cancer Res, 2004,64(1):3761-3766.
8. ROSELL R, TARON M, BARNADAS A, et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer[J]. Cancer Control, 2003,10(4):297-305.
9. ZHOU W, GURUBHAGAVATULA S, LIU G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy [J]. Clin Cancer Res, 2004,10 (15):4939-4943.